"Until recently, vaccines had been a neglected part of drug company portfolios, bedeviled by commodity pricing and concerns about litigation. But a new generation of vaccines has emerged and some of the leading pharmaceutical companies, including Merck and GlaxoSmithKline, will double their vaccine revenues as a share of overall revenues. At the same time, biotechnology companies are attacking infectious diseases through vaccines with the use of novel and enormous promising technologies. This panel will give an overview of those emerging technologies and how they could bolster the already booming market for vaccines."

Objective1: Convince the audience that clinical-stage attrition is the single most important issue facing the pharmaceutical industry today.

Objective2: Provide a compelling rationale for bringing complex biology back into the discovery paradigm.

Objective3: Describe how high-throughput biology can be used to screen for, identify and select the best compounds.